Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 3/20 | 0.36 |
| ▸ | ATP4B | P51164 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628930 | 0.92 | LMNA (0.38) | KDM4EALDH1A1TDP1 | |
| SCHEMBL20351972 | 0.83 | HRH3 (0.43) | KDM4EALDH1A1HRH3 | |
| SCHEMBL1367197 | 0.75 | — | — | |
| SCHEMBL22207120 | 0.74 | FBP1 (0.38) | FPR2 | |
| SCHEMBL22584978 | 0.71 | KDM4E (0.49) | KDM4EALDH1A1TDP1ATP4AATP4B | |
| SCHEMBL9942582 | 0.70 | LMNA (0.36) | KDM4E | |
| SCHEMBL22584976 | 0.68 | KDM4E (0.53) | KDM4EALDH1A1TDP1HRH3MAOB | |
| SCHEMBL30692778 | 0.68 | KDM4E (0.53) | KDM4EALDH1A1TDP1HRH3MAOB | |
| SCHEMBL20500556 | 0.67 | DUT (0.33) | — | |
| SCHEMBL10894213 | 0.66 | KDM4E (0.58) | KDM4EALDH1A1TDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562825-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-02-16 | — | — | EP | disclosed |
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| EP-3562825-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LifeArc (GB) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122550-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122550-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, SMARCC2, OXA1L | KDM4E 3490/4885ALDH1A1 635/4885TDP1 4492/4885 |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, SMARCC2, OXA1L | KDM4E 3490/4885ALDH1A1 635/4885TDP1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.